A cancer treatment rejected twice by federal regulators has now won approval. The Food and Drug Administration granted accelerated approval to Tudriqev, a drug made by the biotech company Replimune, for patients with advanced melanoma. Accelerated approval is a regulatory pathway that lets the FDA greenlight a drug before long-term survival data is confirmed, on the condition that early efficacy signals are strong and patients lack good alternatives.
A troubled path to clearance
The drug, known in clinical development as RP1, had a difficult history with the FDA. Two prior applications were rejected. When Replimune came back a third time, FDA staff still had reservations, specifically about the design and conduct of the company's key clinical trial. A trial design concern is worth explaining: it does not necessarily mean the drug does not work. It means the study structure may make the results harder to interpret with confidence.
The application cleared that hurdle. The FDA's outside advisory committee, a panel of independent experts the agency convenes to review complex or contested drug applications, examined the evidence and voted last week in support of Tudriqev. The panel concluded that the efficacy signal was large enough to support approval. Advisers also weighed the situation facing patients with advanced melanoma: limited options exist, and the urgency of their need was part of the calculus.
What accelerated approval actually requires
Accelerated approval is conditional. The FDA clears the drug based on an intermediate measure of benefit, such as tumor response, rather than waiting for full proof that patients live longer. The company must then run confirmatory trials to provide that evidence. If those trials fail, the approval can be withdrawn.
For Replimune, the clearance ends a long regulatory dispute. For patients, it means Tudriqev is available. The trial conduct questions FDA staff raised do not disappear with approval: they set the terms for what confirmatory evidence will need to show.
The number Replimune has not disclosed
Price determines access as much as approval does in cancer medicine. Without a disclosed cost, neither patients nor insurers can assess what Tudriqev access will look like in practice. Replimune has not yet said what the drug will cost.